Index of /template_files/1402/PR

[ICO]NameLast modifiedSizeDescription

[DIR]Parent Directory  -  
[   ]2018.09.12 Virpax Reports Pre-IND Guidance From FDA for DSF100.pdf22-Feb-2023 18:17 44K 
[   ]2018.12.27 Virpax announces Successful PIND Meeting for LBL100.pdf22-Feb-2023 18:17 164K 
[   ]2019.04.16 Virpax Licenses MET Intranasal Formulation from Nanomerics.pdf22-Feb-2023 18:17 159K 
[   ]2019.04.24 Virpax to Present at ThinkEquity Conference.pdf22-Feb-2023 18:17 144K 
[   ]2019.06.03 Virpax selected for Two Presentations at the 2019 MHSRS.pdf22-Feb-2023 18:17 129K 
[   ]2019.08.06 Virpax to Present at 2019 MHSRS.pdf22-Feb-2023 18:17 86K 
[   ]2019.09.10 VIRPAX BOD Appointment Final.pdf22-Feb-2023 18:17 153K 
[   ]2019.09.17 VIRPAX Appointment Gerald Bruce Final.pdf22-Feb-2023 18:17 151K 
[   ]2020.01.14 Virpax to Develop Its MET Intranasal Enkephalin Formulation 01.14.2020.pdf22-Feb-2023 18:17 159K 
[   ]2020.02.05 Virpax Pharmaceuticals SOMSA DSF100 and NES100 Final.pdf22-Feb-2023 18:17 177K 
[   ]2020.03.02 PIND NES100 Virpax Pharmaceuticals Final.pdf22-Feb-2023 18:17 157K 
[   ]2020.03.19 PIND OSF200 Virpax Pharmaceuticals.pdf22-Feb-2023 18:17 191K 
[   ]2020.04.28 VIRPAX New Board Member_Jacob.pdf22-Feb-2023 18:17 193K 
[   ]2020.06.02 Virpax Pharmaceuticals Announces Appt of Chris Chipman CFO.pdf22-Feb-2023 18:17 171K 
[   ]2020.07.09 Vanila Singh Elected to Virpax Pharmaceuticals BOD.pdf22-Feb-2023 18:17 186K 
[   ]2020.08.24 Virpax Pharma to Develop MMS019.pdf22-Feb-2023 18:17 159K 
[   ]2020.08.31 NES100 Virpax Pharmaceuticals Enters into CRADA for NES100.pdf22-Feb-2023 18:17 157K 
[   ]2020.12.08 MMS019 inhibits SARS-COV-2.pdf22-Feb-2023 18:17 157K 
[   ]2021.02.16 Virpax Pharmaceuticals Announces Pricing of Initial Public Offering.pdf22-Feb-2023 18:17 203K 
[   ]2021.02.19 Virpax Pharmaceuticals Announces Closing of Initial Public Offering.pdf22-Feb-2023 18:17 176K 
[   ]2021.02.23 Virpax_Envelta - IND Enabling Studies Annoucement.pdf22-Feb-2023 18:17 200K 
[   ]2021.03.02 Virpax Pharmaceuticals Announces Newly Issued Patent for Probudur.pdf22-Feb-2023 18:17 129K 
[   ]2021.03.10 Virpax to Initiate IND Enabling Studies Epoladerm.pdf22-Feb-2023 18:17 205K 
[   ]2021.03.22 Virpax to Initiate IND Enabling Studies Probudur.pdf22-Feb-2023 18:17 209K 
[   ]2021.04.05 Virpax_Probudur demonstrates minimal local nerve toxicity.pdf22-Feb-2023 18:17 192K 
[   ]2021.08.17 Virpax Receives FDA Response and Guidance on MMS019.pdf22-Feb-2023 18:17 153K 
[   ]2021.10.01 Virpax to Present at the NobleCon Online Pain Management Investor Forum.pdf22-Feb-2023 18:17 142K 
[   ]2021.10.06 Virpax Signs Agreement to Initiate IND Studies for AnQlar1.pdf22-Feb-2023 18:17 229K 
[   ]2021.12.08 VRPX Reports Successful Results of Tox Pharmacokinetic Studies Epoladerm.pdf22-Feb-2023 18:17 165K 
[   ]2021.12.20 VRPX Announces Clinical Trial Site in Canada for FIH Study of Epoladerm.pdf22-Feb-2023 18:17 194K 
[   ]2021.12.28 Virpax Pharmaceuticals Recaps Milestones and Highlights Product Portfolio.pdf22-Feb-2023 18:17 156K 
[   ]2022.01.04 Virpax to Present at H.C. Wainwright BioConnect Virtual Conference Final.pdf22-Feb-2023 18:17 175K 
[   ]Envelta IND enabling studies - expanded indications Final 06.21.2021 w.logo.pdf22-Feb-2023 18:17 165K 
[   ]LD Micro Conference_Virpax Press Release Final 06.02.2021 Logo.pdf22-Feb-2023 18:17 151K 
[   ]Torreya_Virpax Press Release Final w.logo 04.22.2021.pdf22-Feb-2023 18:17 144K 
[   ]VRPX Announces Closing of $40 Million Public Offering of Common Stock w. logo .pdf22-Feb-2023 18:17 163K 
[   ]VRPX Follow On Press Release Pricing 4834-8259-7114 Final 09.14.2021 w. logo.pdf22-Feb-2023 18:17 168K 
[   ]Virpax Announces MMS019 Manufacturing and Supply Agreement 08.26.2021 w.logo.pdf22-Feb-2023 18:17 151K 
[   ]Virpax Announces Poster Presentation for Envelta at PAINWeek 2021.pdf22-Feb-2023 18:17 151K 
[   ]Virpax Announces Successful Completion of Its Dermal Safety Trials for Epoladerm Final.pdf22-Feb-2023 18:17 165K 
[   ]Virpax Continues to Advance Envelta Development Under CRADA 11.10.2021 Final w.logo.pdf22-Feb-2023 18:17 157K 
[   ]Virpax Earnings Release 2nd Qtr Final 08.10.2021.pdf22-Feb-2023 18:17 308K 
[   ]Virpax Earnings Release Final 05-18-21.pdf22-Feb-2023 18:17 289K 
[   ]Virpax Pharmaceuticals Reports 2021 Third Quarter Final 11.15.2021 w logo.pdf22-Feb-2023 18:17 345K 
[   ]Virpax Provides Progress Update on Product Candidates Final 07.07.2021.pdf22-Feb-2023 18:17 147K 
[   ]VirpaxReportsFavorablePreclinicalSafetyDataforEnvelta.pdf22-Feb-2023 18:17 190K 
[   ]Virpax Strengthens Board of Directors 07.30.21 Final w Logo.pdf22-Feb-2023 18:17 187K 
[   ]Virpax_MMS019 InVivo Data 04.19.2021 Final w logo.pdf22-Feb-2023 18:17 213K 
[   ]Virpax to Develop Intranasal Cannabidiol Product for the Management of Epilepsy 09.20.2021 w logo.pdf22-Feb-2023 18:17 145K 

Apache/2.2.14 (Ubuntu) Server at preview.irdirect.net Port 80